Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis | Zendy

Matthew G. Davey | Zendy; Ferdia Browne | Zendy; Nicola Miller | Zendy; Aoïfe Lowery | Zendy; Michael J. Kerin | Zendy

Open Access

Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis

Author(s) -

Matthew G. Davey,

Ferdia Browne,

Nicola Miller,

Aoïfe Lowery,

Michael J. Kerin

Publication year - 2022

Publication title -

bjs open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.974

H-Index - 9

ISSN - 2474-9842

DOI - 10.1093/bjsopen/zrac028

Subject(s) - breast cancer , medicine , hazard ratio , oncology , meta analysis , human epidermal growth factor receptor 2 , confidence interval , biomarker , cancer , pathological , biology , biochemistry

Achieving a pathological complete response (pCR) is believed to correlate with oncological outcomes in human epidermal growth factor receptor-2-positive (HER2+) breast cancer. However, informed estimation of this survival advantage is often difficult to quantify. The aim of this study was to evaluate the role of pCR as a biomarker of survival in patients treated with neoadjuvant therapies for HER2+ breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research